{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:15:16Z","timestamp":1765368916130},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces Parkinson\u2019s disease (PD)-like neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) via its oxidized product, 1-methyl-4-phenylpyridinium (MPP+), which is transported by the dopamine (DA) transporter into DA nerve terminals. DA receptor subtype 3 (D3 receptor) participates in neurotransmitter transport, gene regulation in the DA system, physiological accommodation via G protein-coupled superfamily receptors and other physiological processes in the nervous system. This study investigated the possible correlation between D3 receptors and MPTP-induced neurotoxicity. A series of behavioral experiments and histological analyses were conducted in D3 receptor-deficient mice, using an MPTP-induced model of PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After the fourth MPTP injection, wild-type animals that received 15 mg\/kg per day displayed significant neurotoxin-related bradykinesia. D3 receptor-deficient mice displayed attenuated MPTP-induced locomotor activity changes. Consistent with the behavioral observations, further neurohistological assessment showed that MPTP-induced neuronal damage in the SNpc was reduced in D3 receptor-deficient mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study indicates that the D3 receptor might be an essential molecule in MPTP-induced PD and provides a new molecular mechanism for MPTP neurotoxicity.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2202-14-76","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T10:14:27Z","timestamp":1375265667000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity"],"prefix":"10.1186","volume":"14","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-yin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-min","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu-gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-hua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,31]]},"reference":[{"key":"3380_CR1","volume-title":"Molecular, Cellular and Medical Aspects","author":"J Sian","year":"1999","unstructured":"Sian J, Youdim M, Riederer P, Gerlach M: MPTP-induced parkinsonian syndrome, basic neurochemistry. Molecular, Cellular and Medical Aspects. Edited by: Siegel GJ. 1999, Philadelphia: Lippincott-Raven, 6","edition":"6"},{"key":"3380_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1749-6632.1992.tb24527.x","volume":"648","author":"I Kopin","year":"1992","unstructured":"Kopin I: Features of the dopaminergic neurotoxin MPTP. Ann N Y Acad Sci. 1992, 648: 96-104. 10.1111\/j.1749-6632.1992.tb24527.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3380_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","volume":"20","author":"P Riederer","year":"2011","unstructured":"Riederer P, Laux G: MAO-inhibitors in parkinson\u2019s disease. Exp Neurobiol. 2011, 20: 1-17. 10.5607\/en.2011.20.1.1.","journal-title":"Exp Neurobiol"},{"key":"3380_CR4","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1046\/j.1471-4159.1997.69031322.x","volume":"69","author":"R Gainetdinov","year":"1997","unstructured":"Gainetdinov R, Fumagalli F, Jones S, Caron M: Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem. 1997, 69: 1322-1325.","journal-title":"J Neurochem"},{"key":"3380_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrneurol.2009.136","volume":"10","author":"W Nanhoe-Mahabier","year":"2009","unstructured":"Nanhoe-Mahabier W, de Laat K, Visser J, Zijlmans J, de Leeuw F, Bloem B: Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol. 2009, 10: 533-541.","journal-title":"Nat Rev Neurol"},{"key":"3380_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMct1208070","volume":"367","author":"M Okun","year":"2012","unstructured":"Okun M: Deep-brain stimulation for parkinson\u2019s disease. N Engl J Med. 2012, 367: 1529-1538. 10.1056\/NEJMct1208070.","journal-title":"N Engl J Med"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"7","author":"C Olanow","year":"2006","unstructured":"Olanow C, Obeso J, Stocchi F: Drug insight: continuous dopaminergic stimulation in the treatment of parkinson\u2019s disease. Nat Clin Pract Neurol. 2006, 7: 382-392.","journal-title":"Nat Clin Pract Neurol"},{"key":"3380_CR8","first-page":"1","volume":"11","author":"S Hisahara","year":"2011","unstructured":"Hisahara S, Shimohama S: Dopamine receptors and parkinson\u2019s disease. Int J Med Chem. 2011, 11: 1-16.","journal-title":"Int J Med Chem"},{"key":"3380_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1126\/science.1066969","volume":"294","author":"A Carlsson","year":"2001","unstructured":"Carlsson A: A paradigmshift in brain research. Science. 2001, 294: 1021-1024. 10.1126\/science.1066969.","journal-title":"Science"},{"key":"3380_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash S, Robinson S, Jaber M, Caron M: Dopamine receptors: from structure to function. Physiol Rev. 1998, 78: 189-225.","journal-title":"Physiol Rev"},{"key":"3380_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/277093a0","volume":"277","author":"J Kebabian","year":"1979","unstructured":"Kebabian J, Calne D: Multiple receptors for dopamine. Nature. 1979, 277: 93-96. 10.1038\/277093a0.","journal-title":"Nature"},{"key":"3380_CR12","first-page":"229","volume":"32","author":"P Seeman","year":"1980","unstructured":"Seeman P: Brain dopamine receptors. Pharmacol Rev. 1980, 32: 229-313.","journal-title":"Pharmacol Rev"},{"key":"3380_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1073\/pnas.93.5.1945","volume":"93","author":"D Accili","year":"1996","unstructured":"Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S: A targetedmutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA. 1996, 93: 1945-1949. 10.1073\/pnas.93.5.1945.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3380_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0896-6273(00)80965-4","volume":"19","author":"M Xu","year":"1997","unstructured":"Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S: Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997, 19: 837-848. 10.1016\/S0896-6273(00)80965-4.","journal-title":"Neuron"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neulet.2010.09.025","volume":"485","author":"T Li","year":"2010","unstructured":"Li T, Hou Y, Yan C, Chen T, Zhao Y, Li S: Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci Lett. 2010, 485: 256-260. 10.1016\/j.neulet.2010.09.025.","journal-title":"Neurosci Lett"},{"key":"3380_CR16","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/00001756-200008030-00012","volume":"11","author":"A Carta","year":"2000","unstructured":"Carta A, Gerfen C, Steiner H: Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport. 2000, 11: 2395-2399. 10.1097\/00001756-200008030-00012.","journal-title":"Neuroreport"},{"key":"3380_CR17","doi-asserted-by":"publisher","first-page":"38944","DOI":"10.1074\/jbc.M005064200","volume":"275","author":"C Schmauss","year":"2000","unstructured":"Schmauss C: A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D1 receptor-mediated neocortical c-fos responses in mice deficient for D2 and D3 receptors. J Biol Chem. 2000, 275: 38944-38948.","journal-title":"J Biol Chem"},{"key":"3380_CR18","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1523\/JNEUROSCI.22-13-05619.2002","volume":"22","author":"S Glickstein","year":"2002","unstructured":"Glickstein S, Hof P, Schmauss C: Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. Neurosci. 2002, 22: 5619-5629.","journal-title":"Neurosci"},{"key":"3380_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11064-008-9781-y","volume":"34","author":"V D\u2019Agata","year":"2009","unstructured":"D\u2019Agata V, Tiralongo A, Castorina A: Parkin expression profile in dopamine d3 receptor knock-out mice brains. Neurochem Res. 2009, 34: 327-332. 10.1007\/s11064-008-9781-y.","journal-title":"Neurochem Res"},{"key":"3380_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of parkinson\u2019s disease. Nat Protoc. 2007, 2: 141-151.","journal-title":"Nat Protoc"},{"key":"3380_CR21","first-page":"435","volume":"50","author":"N Ogawa","year":"1985","unstructured":"Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y: A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol. 1985, 50: 435-441.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"3380_CR22","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1038\/emboj.2012.170","volume":"31","author":"N Exner","year":"2012","unstructured":"Exner N, Lutz A, Haass C, Winklhofer K: Mitochondrial dysfunction in Parkinson\u2019s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31: 3038-3062. 10.1038\/emboj.2012.170.","journal-title":"EMBO J"},{"key":"3380_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneuro0126","volume":"2","author":"C Klein","year":"2006","unstructured":"Klein C, Schlossmacher M: The genetics of parkinson disease: Implications for neurological care. Nat Clin Pract Neurol. 2006, 2: 136-146.","journal-title":"Nat Clin Pract Neurol"},{"key":"3380_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.55782\/ane-2011-1847","volume":"71","author":"H Yokoyama","year":"2011","unstructured":"Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson\u2019s disease. Acta Neurobiol Exp (Wars). 2011, 71: 269-280.","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"3380_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1046\/j.1471-4159.2003.01801.x","volume":"86","author":"Y Sagi","year":"2003","unstructured":"Sagi Y, Weinstock M, Youdim M: Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem. 2003, 86: 290-297.","journal-title":"J Neurochem"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-14-76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T19:20:40Z","timestamp":1715800840000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-14-76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-14-76","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,31]]},"assertion":[{"value":"5 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"76"}}